#None #Cancer Treatment #Intensity Therapeutics #INT230-6

Intensity Therapeutics Announces Groundbreaking Clinical Results of INT230-6

In a significant advancement in cancer treatment, Intensity Therapeutics, Inc. has announced the publication of important clinical trial results for INT230-6, a novel therapy designed for patients dealing with metastatic or refractory cancers. This landmark study has been published in eBioMedicine, a distinguished journal in the Lancet Discovery Science family.

Overview of the Study

The clinical trial, titled “Safety and Efficacy of Intratumourally Administered INT230-6 in Adult Patients with Advanced Solid Tumours Results from an Open-Label Phase 1/2 Dose Escalation Study,” was crucial in assessing the therapy’s effectiveness and safety. It highlights data concerning disease control rates, overall survival, immune activation, and the therapy’s unique abscopal effects. This comprehensive evaluation reveals promising implications for patients who have exhausted available treatment options.

The study involved a cohort of 64 patients with various advanced cancers that had become resistant to standard therapies. Results indicated a disease control rate of 75%, with a median overall survival of 11.9 months. Remarkably, those among this group suffering from metastatic sarcoma who received INT230-6 showed an even higher survival rate lasting an average of 21.3 months.

Mechanism of Action and Results

INT230-6 employs a sophisticated mechanism that enables direct intratumoral injection of cytotoxic agents, which not only destroys cancer cells but also activates immune responses against tumors. The results underscore its potential to treat cancers previously deemed resistant. Notably, in patients who received more than 40% of their tumor burden treated with the drug, the disease control rate surged to 83.3%, contrasting sharply with a 50% rate in those receiving less.

Furthermore, about 20% of patients experienced what is referred to as abscopal effects, where untreated tumors shrank as a secondary result of localized treatment, indicating systemic immune activation.

The trial also revealed that intratumoral administration of INT230-6 leads to decreased proliferation of cancer cells while simultaneously increasing the presence of activated T cells in the tumor's microenvironment, crucial for a robust anti-cancer response. Safety measures proved effective, with only a small number of patients reporting grade 3 adverse events without any severe toxicities.

Future Implications

Dr. Jacob Stephen Thomas from the University of Southern California, who participated in the study, summarised the potential of INT230-6, stating, “This therapy not only shows a great promise in local tumor control but also indicates a spice for systemic efficacy.”

With the implementation of randomized controlled trials, including a Phase 3 study in sarcoma, Intensity Therapeutics aims to further investigate the benefits of INT230-6 in a broader clinical context.

Lewis H. Bender, the company’s CEO, expressed optimism regarding these findings. He noted that these results pave the way for a new therapeutic approach that may decrease the reliance on conventional methods such as systemic chemotherapy, particularly for malignancies that often exhibit poor immunogenicity.

Company Vision

Intensity Therapeutics underscores a mission: to innovate cancer treatments through groundbreaking research and technology. With successful trials already in existence—such as the Phase 2 INVINCIBLE-2 study for locally advanced breast cancer—the company is keen to continue making strides in the fight against cancer.

To further discuss these findings, Intensity will host a conference call on October 31, 2025, featuring key authors of the study. Those interested can access the call online and are encouraged to join in to gain insights directly from the researchers involved.